350 related articles for article (PubMed ID: 9920285)
1. Tyrosine kinase activity of purified recombinant cytoplasmic domain of platelet-derived growth factor beta-receptor (beta-PDGFR) and discovery of a novel inhibitor of receptor tyrosine kinases.
Zaman GJ; Vink PM; van den Doelen AA; Veeneman GH; Theunissen HJ
Biochem Pharmacol; 1999 Jan; 57(1):57-64. PubMed ID: 9920285
[TBL] [Abstract][Full Text] [Related]
2. A dual inhibitor of platelet-derived growth factor beta-receptor and Src kinase activity potently interferes with motogenic and mitogenic responses to PDGF in vascular smooth muscle cells. A novel candidate for prevention of vascular remodeling.
Waltenberger J; Uecker A; Kroll J; Frank H; Mayr U; Bjorge JD; Fujita D; Gazit A; Hombach V; Levitzki A; Böhmer FD
Circ Res; 1999 Jul; 85(1):12-22. PubMed ID: 10400906
[TBL] [Abstract][Full Text] [Related]
3. Platelet-derived growth factor (PDGF)-induced tyrosine phosphorylation of the low density lipoprotein receptor-related protein (LRP). Evidence for integrated co-receptor function betwenn LRP and the PDGF.
Loukinova E; Ranganathan S; Kuznetsov S; Gorlatova N; Migliorini MM; Loukinov D; Ulery PG; Mikhailenko I; Lawrence DA; Strickland DK
J Biol Chem; 2002 May; 277(18):15499-506. PubMed ID: 11854294
[TBL] [Abstract][Full Text] [Related]
4. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class.
Buchdunger E; Zimmermann J; Mett H; Meyer T; Müller M; Regenass U; Lydon NB
Proc Natl Acad Sci U S A; 1995 Mar; 92(7):2558-62. PubMed ID: 7708684
[TBL] [Abstract][Full Text] [Related]
5. Differences in substrate specificities of alpha and beta platelet-derived growth factor (PDGF) receptors. Correlation with their ability to mediate PDGF transforming functions.
Heidaran MA; Beeler JF; Yu JC; Ishibashi T; LaRochelle WJ; Pierce JH; Aaronson SA
J Biol Chem; 1993 May; 268(13):9287-95. PubMed ID: 8387491
[TBL] [Abstract][Full Text] [Related]
6. Ligand-induced polyubiquitination of receptor tyrosine kinases.
Mori S; Claesson-Welsh L; Okuyama Y; Saito Y
Biochem Biophys Res Commun; 1995 Aug; 213(1):32-9. PubMed ID: 7639752
[TBL] [Abstract][Full Text] [Related]
7. Indolocarbazoles: potent and selective inhibitors of platelet-derived growth factor receptor autophosphorylation.
Spacey GD; Uings IJ; Slater M; Hirst S; Bonser RW
Biochem Pharmacol; 1998 Feb; 55(3):261-71. PubMed ID: 9484791
[TBL] [Abstract][Full Text] [Related]
8. Signal transduction through a biomolecular receptor tyrosine protein kinase composed of a platelet-derived growth factor receptor-CD4 chimera and the nonreceptor tyrosine protein kinase Lck.
Adam D; Klages S; Bishop P; Mahajan S; Escobedo JA; Bolen JB
J Biol Chem; 1993 Sep; 268(26):19882-8. PubMed ID: 8366126
[TBL] [Abstract][Full Text] [Related]
9. Bis(1H-2-indolyl)-1-methanones as inhibitors of the hematopoietic tyrosine kinase Flt3.
Teller S; Krämer D; Böhmer SA; Tse KF; Small D; Mahboobi S; Wallrapp C; Beckers T; Kratz-Albers K; Schwäble J; Serve H; Böhmer FD
Leukemia; 2002 Aug; 16(8):1528-34. PubMed ID: 12145694
[TBL] [Abstract][Full Text] [Related]
10. Phosphotyrosine binding domain-dependent upregulation of the platelet-derived growth factor receptor alpha signaling cascade by transforming mutants of Cbl: implications for Cbl's function and oncogenicity.
Bonita DP; Miyake S; Lupher ML; Langdon WY; Band H
Mol Cell Biol; 1997 Aug; 17(8):4597-610. PubMed ID: 9234717
[TBL] [Abstract][Full Text] [Related]
11. Beta-platelet-derived growth factor receptor mediates motility and growth of Ewing's sarcoma cells.
Uren A; Merchant MS; Sun CJ; Vitolo MI; Sun Y; Tsokos M; Illei PB; Ladanyi M; Passaniti A; Mackall C; Toretsky JA
Oncogene; 2003 Apr; 22(15):2334-42. PubMed ID: 12700668
[TBL] [Abstract][Full Text] [Related]
12. Two signaling molecules share a phosphotyrosine-containing binding site in the platelet-derived growth factor receptor.
Nishimura R; Li W; Kashishian A; Mondino A; Zhou M; Cooper J; Schlessinger J
Mol Cell Biol; 1993 Nov; 13(11):6889-96. PubMed ID: 7692233
[TBL] [Abstract][Full Text] [Related]
13. Identification of a domain within the carboxyl-terminal region of the beta platelet-derived growth factor (PDGF) receptor that mediates the high transforming activity of PDGF.
Uren A; Yu JC; Li W; Chung IY; Mahadevan D; Pierce JH; Heidaran MA
J Biol Chem; 1996 May; 271(19):11051-4. PubMed ID: 8626645
[TBL] [Abstract][Full Text] [Related]
14. Selective inhibition of platelet-derived growth factor (PDGF) receptor autophosphorylation and PDGF-mediated cellular events by a quinoline derivative.
Yagi M; Kato S; Kobayashi Y; Kubo K; Oyama S; Shimizu T; Nishitoba T; Isoe T; Nakamura K; Ohashi H; Kobayashi N; Iinuma N; Osawa T; Onose R; Osada H
Exp Cell Res; 1997 Aug; 234(2):285-92. PubMed ID: 9260896
[TBL] [Abstract][Full Text] [Related]
15. Tyrosine phosphatase SHP-2 is involved in regulation of platelet-derived growth factor-induced migration.
Qi JH; Ito N; Claesson-Welsh L
J Biol Chem; 1999 May; 274(20):14455-63. PubMed ID: 10318871
[TBL] [Abstract][Full Text] [Related]
16. Common and distinct elements in insulin and PDGF signaling.
Myers MG; Cheatham B; Fisher TL; Jachna BR; Kahn CR; Backer JM; White MF
Ann N Y Acad Sci; 1995 Sep; 766():369-87. PubMed ID: 7486683
[TBL] [Abstract][Full Text] [Related]
17. Assessing the activity of cediranib, a VEGFR-2/3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR family.
Brave SR; Ratcliffe K; Wilson Z; James NH; Ashton S; Wainwright A; Kendrew J; Dudley P; Broadbent N; Sproat G; Taylor S; Barnes C; Silva JC; Farnsworth CL; Hennequin L; Ogilvie DJ; Jürgensmeier JM; Shibuya M; Wedge SR; Barry ST
Mol Cancer Ther; 2011 May; 10(5):861-73. PubMed ID: 21441409
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of growth factor-mediated tyrosine phosphorylation in vascular smooth muscle by PD 089828, a new synthetic protein tyrosine kinase inhibitor.
Dahring TK; Lu GH; Hamby JM; Batley BL; Kraker AJ; Panek RL
J Pharmacol Exp Ther; 1997 Jun; 281(3):1446-56. PubMed ID: 9190882
[TBL] [Abstract][Full Text] [Related]
19. Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation.
Kovalenko M; Gazit A; Böhmer A; Rorsman C; Rönnstrand L; Heldin CH; Waltenberger J; Böhmer FD; Levitzki A
Cancer Res; 1994 Dec; 54(23):6106-14. PubMed ID: 7954456
[TBL] [Abstract][Full Text] [Related]
20. Ligand-independent trans-activation of the platelet-derived growth factor receptor by reactive oxygen species requires protein kinase C-delta and c-Src.
Saito S; Frank GD; Mifune M; Ohba M; Utsunomiya H; Motley ED; Inagami T; Eguchi S
J Biol Chem; 2002 Nov; 277(47):44695-700. PubMed ID: 12226102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
